All In Biotech

Drug Trial Radar · NCT03440372

Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

Last checked: Nov 20, 2026Latest source record: Nov 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 625 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

625

Actual

Start

Feb 27, 2018

Primary completion

Oct 1, 2024

Study completion Oct 1, 2024

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Feb 22, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to explore the effect of oral ozanimod as an induction treatment for participants with moderately to severely active Crohn's Disease.

Conditions

  • Crohn Disease

Interventions

  • OzanimodDrug

    Specified dose on specified days

  • PlaceboOther

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent of Participants With a Crohn's Disease Activity Index (CDAI) Score < 150 at Week 12Time frame: At Week 12

Locations

408 sites in 35 countries. Site status is shown where the registry gives one.

  • Holland Center for Family Health

    Peoria, Arizona

  • Local Institution - 026

    North Little Rock, Arkansas

  • Local Institution - 284

    Camarillo, California

  • Local Institution - 165

    Chula Vista, California

  • Local Institution - 039

    Garden Grove, California

  • San Diego Clinical Trials

    La Mesa, California

  • Local Institution - 061

    Los Angeles, California

  • Local Institution - 110

    Los Angeles, California

  • Local Institution - 140

    Mission Viejo, California

  • Alliance Clinical Research

    Oceanside, California

  • Local Institution - 027

    Orange, California

  • Palo Alto Center-Palo Alto Medical Foundation Research Institute

    Palo Alto, California

  • Local Institution - 006

    Rialto, California

  • Local Institution - 003

    San Diego, California

  • Local Institution - 297

    Lakewood, Colorado

  • Local Institution - 225

    Bristol, Connecticut

  • Local Institution - 091

    New Haven, Connecticut

  • Local Institution - 062

    Clearwater, Florida

  • Local Institution - 218

    Gainesville, Florida

  • Local Institution - 203

    Hialeah, Florida

  • Harmony Medical Research Institute

    Hialeah, Florida

  • Local Institution - 078

    Hialeah, Florida

  • Local Institution - 179

    Hollywood, Florida

  • Local Institution - 101

    Homestead, Florida

  • Local Institution - 016

    Largo, Florida

  • Local Institution - 199

    Miami, Florida

  • LCC Medical Research Institute, LLC

    Miami, Florida

  • Local Institution - 169

    Miami, Florida

  • Local Institution - 090

    Naples, Florida

  • Local Institution - 214

    New Smyrna Beach, Florida

  • Local Institution - 076

    Orlando, Florida

  • Local Institution - 098

    Port Orange, Florida

  • Local Institution - 226

    Tampa, Florida

  • Local Institution - 149

    Tampa, Florida

  • Local Institution - 114

    Weeki Wachee, Florida

  • Local Institution - 205

    Atlanta, Georgia

  • Local Institution - 222

    Atlanta, Georgia

  • Local Institution - 019

    Atlanta, Georgia

  • Local Institution - 063

    Atlanta, Georgia

  • Local Institution - 074

    Columbus, Georgia

Showing 40 of 408 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.